• 2022-09
  • 2022-08
  • 2022-07
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br The gene silencing and cell death


    The gene silencing and cell death mediating MDEA/DOPE nano-particles described in this study could potentially be used to treat non-resectable solid tumors, for example, by intra-tumoral injections. The siRNA could be directed towards cancer oncogenes and/or drug re-sistance genes like MDR1. The penetration of our rather large nano-particles through a dense solid tumor would need to be studied how-ever.
    5. Conclusion
    The cationic lipid MDEA forms nanoparticles when combined with siRNA and these induce sequence specific gene silencing in cancer cells. The addition of DOPE increases transfection efficiency to a maximum of 93% which was achieved at a DOPE to MDEA to ratio of 3 and an N:P ratio of 6. Experiments with the model drug Nile red shows that small molecular weight drugs can be stably encapsulated in the particles and be co-delivered along siRNA to the cytoplasm of cells. Sufficient eto-poside could also be included in the nanoparticles to give effective well concentrations of over 10 μM while still achieving 83% and 77% gene silencing, respectively. Etoposide inclusion induced cell death in the lung cancer and oral cancer cell lines H1299 and Cal27, respectively. In conclusion, a novel drug delivery system for co-delivery of siRNA and chemotherapeutics was developed; the system may hold value in the treatment of non-resectable chemotherapy resistant tumors.
    The authors would like to thank Jørgen Kjems and Anne Chauchereau who provided the H1299 and Cal27 L-Glutamine and the tech-nical staff from the University of Southern Denmark. We would also like to thank Aleksandra Rojek for help with transmission electron micro-scopy, The Danish Molecular Biomedical Imaging Center (DaMBIC) for use of Confocal Microscopy and the Carlsberg Foundation for funding (Carlsberg start up grant to EAC).
    Bartlett, D.W., Davis, M.E., 2006. Insights into the kinetics of siRNA-mediated gene si-lencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 34 (1), 322–333.
    Chen, G., Kronenberger, P., Teugels, E., Umelo, I.A., De Grève, J., 2012. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med. 10, 28.
    Greenspan, P., Fowler, S.D., 1985. Spectrofluorometric studies of the lipid probe, Nile red.
    Mahmodabady, A.Z., Javadi, H.R., Kamali, M., Najafi, A., Hojati, Z., 2010. Bcr-abl si-lencing by specific small-interference RNA expression vector as a potential treatment for chronic myeloid leukemia. Iran. Biomed. J. 14 (1–2), 1–8. Manju, Saraswathy, Shaoqin, Gong, 2014. Recent developments in the co-delivery of siRNA and small molecule anticancer drugs for cancer treatment. Mater. Today 17 (6), 298–306.
    Mochizuki, S., Kanegae, N., Nishina, K., Kamikawa, Y., Koiwai, K., Masunaga, H., Sakurai, K., 2013. The role of the helper lipid dioleoylphosphatidylethanolamine (DOPE) for DNA transfection cooperating with a cationic lipid bearing ethylenediamine.
    Nitiss, J.L., 2009. Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev.
    Perepelyuk, M., Shoyele, O., Birbe, R., Thangavel, C., Liu, Y., Den, R.B., Snook, A.E., Lu, B., Shoyele, S.A., 2017. siRNA-encapsulated hybrid nanoparticles target mutant K-ras and inhibit metastatic tumor burden in a mouse model of lung cancer. Mol. Ther.
    Petrova, N.S., Zenkova, M.A., Chernolovskaya, E.L., 2003. Structure - functions relations in small interfering RNAs. In: Andrade, A.O., Pereira, A.A., Naves, E.M.M., Soares, A.B. (Eds.), Practical Applications in Biomedical Engineering. Intech.
    Snipstad, S., Westrøm, S., Mørch, Y., Afadzi, M., Åslund, A.K.O., de Lange Davies, C., 2014. Contact-mediated intracellular delivery of hydrophobic drugs from polymeric nanoparticles. Cancer Nanotechnol. Basic Transl. Clin. Res. 5, 8.